OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights
02. November 2017 16:05 ET
|
OncoMed Pharmaceuticals, Inc.
Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...
OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
13. September 2017 08:05 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
OncoMed Highlights New Data Presented at the American Association for Cancer Research Annual Meeting 2017
05. April 2017 08:00 ET
|
OncoMed Pharmaceuticals, Inc.
WASHINGTON and REDWOOD CITY, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
19. April 2016 09:00 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the...
OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
16. März 2016 16:30 ET
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...